Home›Stock Screener›Krsnaa Diagnostics›Intrinsic Value

Krsnaa Diagnostics Intrinsic Value

Krsnaa Diagnostics intrinsic value. Krsnaa Diagnostics (KRSNAA) median intrinsic value is ₹750.00 from 10 valuation models (range ₹155–₹1225), vs current price ₹515.65 — +45.4% upside (Trading Below Calculated Value), margin of safety 31.2%. For current market price and key ratios, visit KRSNAA stock price BSE.

Market Price (CMP)
₹515.65
Primary Intrinsic Value
₹672.32
Market Cap
₹825.0 Cr
+45.4% Upside
Median Value
₹750.00
Value Range
₹155 - ₹1225
Assessment
Trading Below Calculated Value
Safety Margin
31.2%

KRSNAA Valuation Methods Summary — DCF, Graham Number & P/E

Krsnaa Diagnostics intrinsic value across 10 models vs current price ₹515.65 — upside/downside and value range per method. Analyse Krsnaa Diagnostics shareholding analysis to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹672.32 ₹537.86 - ₹806.78 +30.4% EPS: ₹30.56, Sector P/E: 22x
Book Value Method asset ₹1225.00 ₹1102.50 - ₹1347.50 +137.6% Book Value/Share: ₹612.50, P/B: 2.0x
Revenue Multiple Method revenue ₹1031.30 ₹928.17 - ₹1134.43 +100.0% Revenue/Share: ₹692.50, P/S: 2.0x
EBITDA Multiple Method earnings ₹1031.30 ₹928.17 - ₹1134.43 +100.0% EBITDA: ₹308.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹761.38 ₹609.10 - ₹913.66 +47.7% CF Growth: 2.8%, Discount: 15%
PEG Ratio Method growth ₹195.58 ₹176.02 - ₹215.14 -62.1% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹472.15 ₹424.94 - ₹519.37 -8.4% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹750.00 ₹675.00 - ₹825.00 +45.4% ROE: 10.2%, P/E Multiple: 12x
Graham Defensive Method conservative ₹648.96 ₹584.06 - ₹713.86 +25.9% EPS: ₹30.56, BVPS: ₹612.50
Dividend Yield Method dividend ₹154.69 ₹139.22 - ₹170.16 -70.0% DPS: ₹2.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

KRSNAA Intrinsic Value vs Market Price — All Valuation Models

Krsnaa Diagnostics fair value range ₹155–₹1225 vs current market price ₹515.65 across 10 valuation models. Browse KRSNAA income statement for revenue, profit, balance sheet and cash flow data.

KRSNAA Intrinsic Value Analysis — Undervalued or Overvalued?

Krsnaa Diagnostics median intrinsic value ₹750.00, current price ₹515.65 — Trading Below Calculated Value by 45.4%, margin of safety 31.2%.

What is the intrinsic value of KRSNAA?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Krsnaa Diagnostics (KRSNAA) is ₹750.00 (median value). With the current market price of ₹515.65, this represents a +45.4% variance from our estimated fair value.

The valuation range spans from ₹154.69 to ₹1225.00, indicating ₹154.69 - ₹1225.00.

Is KRSNAA undervalued or overvalued?

Based on our multi-method analysis, Krsnaa Diagnostics (KRSNAA) appears to be trading below calculated value by approximately 45.4%.

KRSNAA Financial Health — Key Ratios vs Industry Benchmarks

Krsnaa Diagnostics financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 10.2% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 26.0% Industry Standard: 20%+ Above 20% Indicates operational efficiency level
Asset Turnover Ratio 0.61x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

KRSNAA Cash Flow Quality — Operating & Free Cash Flow

Krsnaa Diagnostics operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹143 Cr ₹-55 Cr Positive Operating Cash Flow 6/10
March 2025 ₹87 Cr ₹37 Cr Positive Free Cash Flow 7/10
March 2024 ₹24 Cr ₹-41 Cr Positive Operating Cash Flow 6/10
March 2023 ₹76 Cr ₹22 Cr Positive Free Cash Flow 7/10
March 2022 ₹128 Cr ₹8 Cr Positive Free Cash Flow 7/10